Pricing Log in Create free account
Saturday 17 October 2026 Export SRTS’s income statement to Excel — free account

Sensus Healthcare, Inc.

SRTS Healthcare Medical Devices

Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024. In the quarter to June 2026, revenue fell 68.7%, EPS fell 783.3% and free cash flow fell 201.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.77 0.00 0.00%
Market cap
$45.6M
P/E
0.0×
Fwd P/E
−6.9×
Dividend yield
—
F-score
4/9
Altman Z
8.85
Beneish M
−3.66
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.73
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 6 — — 1 — — 1 — — 5 — —
Sell — — — — — — — — — — — —
Insider Ownership 18.66%

Capital & Financial Ratios $m

Market Cap 45.60
Revenue 17.51
Net Income (15.48)
Free Cash Flow (6.97)
Net Debt (15.19)
Current Ratio 8.71 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.92) (negative: loss-making)
P/S ratio 2.60
P/B ratio 1.24
Past 5Y EPS Growth —
This Y EPS Growth (68.62%) (below 0%: weak)
Next Y EPS Growth 85.80% (at or above 15%: strong)
Next Y revenue growth (30.39%) (below 0%: weak)
Next 5Y EPS Growth (5.59%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.1×, against a ten-year median of 2.6×; over the ten years it ranged from 0.8× in 2023 to 6.9× in 2021.
P/S against its own 10 years 31.69%
10-year low 10-year high
P/B against its own 10 years 13.06%
10-year low 10-year high
EV/Sales against its own 10 years 31.45%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 23 22 22 15
Receivables 11 20 6 2
Inventory 15 13 16 19
Other — — — —
50 57 46 38
2023 2024 2025 Q'26
Payables 3 5 3 3
ST’ Debt — — — —
Other 1 0 0 0
4 6 5 4

Compound Annual Growth %

10y 5y 3y
Sales 10.34% 23.47% (14.86%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 23.30% 17.48% 0.02%

Revenue $m

Mar Jun Sep Dec Year
’26 3 2 — — —
’25 8 7 7 5 27
’24 11 9 9 13 42
’23 3 5 4 13 24
’22 10 12 9 13 45
’21 3 5 6 13 27
’20 2 1 2 5 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) 3 2 (2) 1
’24 (8) 4 4 (1) (1)
’23 (6) 1 0 3 (2)
’22 3 2 4 (10) (1)
’21 (1) 1 1 (2) 0
’20 0 2 (3) 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) 3 2 (2) 0
’24 (8) 4 4 (1) (1)
’23 (6) 1 0 3 (2)
’22 18 2 4 (10) 13
’21 (1) 2 1 (2) 0
’20 0 2 (3) 0 (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.53) — — —
’25 (0.16) (0.06) (0.06) (0.19) (0.47)
’24 0.14 0.10 0.07 0.09 0.41
’23 (0.12) (0.02) (0.09) 0.26 0.03
’22 0.97 0.21 0.11 0.17 1.46
’21 (0.07) (0.02) 0.01 0.32 0.25
’20 (0.22) (0.16) (0.10) 0.06 (0.42)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.67 3.38 5.00 3.31 1.76 3.08 5.58 1.79 2.37 3.03

Analyst estimates 2026–2028

Powerpack
High 6.69 6.25 8.88 9.23 4.99 8.55 15.25 9.62 9.33 9.08
People
People Employees 37 45 48 53 42 37 42 35 54 60
Revenue/emp, $m 0.40 0.46 0.55 0.51 0.23 0.73 1.06 0.70 0.77 0.46
Income, $m
Income, $m Revenue 15 21 26 27 10 27 45 24 42 27
Gross margin, % 66.48 67.03 63.99 64.40 54.81 62.82 66.53 57.61 58.44 43.18
EBT 0 (4) (2) (2) (7) 4 28 1 9 (10)
EBT margin, % (2.34) (18.02) (7.65) (6.24) (71.38) 15.23 62.85 2.67 21.58 (35.02)
Net income 0 (4) (2) (2) (7) 4 24 0 7 (8)
Depreciation 0 0 1 1 1 1 1 0 0 1
Per share, $
Per share, $ Revenue 1.23 1.56 1.87 1.68 0.58 1.64 2.70 1.50 2.56 1.68
Earnings (0.03) (0.28) (0.14) (0.10) (0.42) 0.25 1.47 0.03 0.41 (0.47)
Cash flow (0.07) (0.23) (0.61) (0.13) (0.03) (0.02) (0.09) (0.13) (0.05) 0.03
Capex (0.02) (0.02) (0.06) (0.02) (0.02) 0.01 0.90 (0.01) (0.02) (0.01)
Free cash flow (0.09) (0.25) (0.67) (0.15) (0.05) (0.01) 0.81 (0.14) (0.07) 0.02
Book value 1.27 0.88 1.87 1.73 1.31 1.58 2.92 3.00 3.42 2.95
Shares, m 12 13 14 16 16 16 16 16 16 16
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 30.08 4.83 83.00 17.30 0.00
P/S 4.26 3.66 3.96 2.11 6.62 4.40 2.61 1.66 2.70 2.36
P/B 4.13 6.46 3.95 2.05 2.95 4.57 2.42 0.83 2.02 1.35
EV/Sales 3.53 3.31 3.60 1.75 5.68 4.08 2.17 0.95 2.31 1.77
EV/FCF (46.02) (20.36) (10.09) (19.07) (68.56) (702.42) 7.19 (9.94) (87.32) 146.81
Cash, $m
Cash, $m Operating cash flow (1) (3) (9) (2) 0 0 (1) (2) (1) 1
Capex 0 0 (1) 0 0 0 15 0 0 0
Free cash flow (1) (3) (9) (3) (1) 0 13 (2) (1) 0
Balance, $m
Balance, $m Working capital 13 13 26 28 20 25 46 45 51 41
Total debt — 2 — 1 1 0 1 — — —
Net debt (12) (9) (15) (15) (15) (15) (26) (23) (22) (22)
Shareholders’ equity 15 12 26 28 21 26 48 49 56 48
Returns, %
Returns, % ROA (2.42) (19.64) (7.77) (4.84) (21.06) 13.67 54.50 0.88 11.47 (13.40)
ROIC (6.02) (85.89) (11.31) (9.83) (78.10) 22.40 41.11 (0.93) 14.97 (24.76)
ROE (3.27) (27.53) (10.61) (6.24) (27.62) 17.34 65.45 1.00 12.70 (14.85)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Sensus Healthcare, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MYO Myomo, Inc. $51.5M — (loss-making) — (loss-making) +21.26% (above 0%: growing) n/m +80.02% (above 0%: growing) 72.13% (19.26%) Compare
COCH Envoy Medical, Inc. $49.9M — (loss-making) — (loss-making) −34.62% (below 0%: shrinking) n/m −22.44% (below 0%: shrinking) (445.10%) (10,919.61%) Compare
MDAI Spectral AI, Inc. $49.6M — (loss-making) — (loss-making) −30.42% (below 0%: shrinking) n/m −21.86% (below 0%: shrinking) 31.58% (122.70%) Compare
TLIS Talis Biomedical Corporation $46.3M — (loss-making) — (loss-making) −94.01% (below 0%: shrinking) n/m +23.80% (above 0%: growing) 91.78% 0.00% Compare
SRTS Sensus Healthcare, Inc. $45.6M — (loss-making) — (loss-making) −68.69% (below 0%: shrinking) n/m −201.65% (below 0%: shrinking) 33.58% (138.86%)
TELA TELA Bio, Inc. $45.6M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%) Compare
SNWV Sanuwave Health Inc. $44.5M 3.0× — (loss-making) −3.13% (below 0%: shrinking) n/m +86.75% (above 0%: growing) 76.23% (2.88%) Compare
XTNT Xtant Medical Holdings, Inc. $42.5M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
RPID Rapid Micro Biosystems, Inc. $42.4M — (loss-making) — (loss-making) +10.91% (above 0%: growing) n/m −23.97% (below 0%: shrinking) 15.05% (152.99%) Compare
Median of peers $45.9M — — −17.45% — −19.79% 65.01% (43.96%)

All 149 Medical Devices stocks →

Sensus Healthcare, Inc. (SRTS) key facts

  • Concern: Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024.
  • Sensus Healthcare, Inc. (SRTS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SRTS traded at $2.77, a market capitalization of $45.6 million.
  • Return on equity was −14.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 8.85 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Sensus Healthcare, Inc. (SRTS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SRTS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com